India’s FoPE seeks a 10-year exemption for patented and low-cost drugs from price controls. Requests include DPCO and 12% GST adjustments due to 15-130% ingredient cost rises. Presenting to the DoP secretary, FoPE cites working capital issues prompting overseas research. Supported by IPA, Harish Jain stressed necessary revisions.
